Stockscreener 앱 받기
30.55
3.14%
-0.99
시간 외 거래:
30.40
-0.15
-0.49%
전일 마감가:
$31.54
열려 있는:
$31.6
하루 거래량:
564.05K
Relative Volume:
0.66
시가총액:
$1.37B
수익:
-
순이익/손실:
$-47.20M
주가수익비율:
-19.52
EPS:
-1.5653
순현금흐름:
$-43.65M
1주 성능:
-1.13%
1개월 성능:
-7.87%
6개월 성능:
+147.77%
1년 성능:
+67.40%
1일 변동 폭
$29.63
$31.61
1주일 범위
$29.63
$32.05
52주 변동 폭
$4.8069
$35.55
Mbx Biosciences Inc Stock (MBX) Company Profile
명칭
Mbx Biosciences Inc
전화
(317) 989-3100
주소
11711 N. MERIDIAN STREET, CARMEL
MBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
30.55 | 1.42B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 개시 | Goldman | Sell |
| 2025-11-04 | 개시 | TD Cowen | Buy |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-08-15 | 재개 | Jefferies | Buy |
| 2025-08-05 | 개시 | Mizuho | Outperform |
| 2025-07-16 | 개시 | Oppenheimer | Outperform |
| 2025-04-10 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | JP Morgan | Overweight |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Stifel | Buy |
모두보기
Mbx Biosciences Inc 주식(MBX)의 최신 뉴스
Commit To Purchase Mbx Biosciences At $20, Earn 25% Using Options - Nasdaq
MBX Biosciences (NASDAQ:MBX) Stock Price Down 5.8%Here's What Happened - MarketBeat
MBX Biosciences initiated with a sell at Goldman Sachs - MSN
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Mbx Biosciences stock hits all-time high of 34.85 USD By Investing.com - Investing.com Nigeria
MBX Biosciences (NASDAQ:MBX) Stock Price Up 10.8%Still a Buy? - MarketBeat
Mbx Biosciences stock hits all-time high of 34.85 USD - Investing.com
MBX Biosciences price target raised to $50 from $45 at Stifel - MSN
Take Profit: Will MBX Biosciences Inc stock keep outperforming rivalsJuly 2025 Pullbacks & Capital Efficiency Focused Ideas - moha.gov.vn
MBX Biosciences, Inc.(NasdaqGS:MBX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) added to NASDAQ Biotechnology Index - marketscreener.com
Dip Buying: Will MBX Biosciences Inc stock keep outperforming rivalsJuly 2025 Intraday Action & Stock Portfolio Risk Control - moha.gov.vn
MBX Biosciences (NASDAQ:MBX) Upgraded at Wall Street Zen - MarketBeat
How sustainable is MBX Biosciences Inc. stock dividend payoutPortfolio Profit Report & Safe Entry Point Alerts - Улправда
Stifel maintains MBX Biosciences (MBX) buy recommendation - MSN
Will MBX Biosciences Inc. stock attract ESG investorsWeekly Profit Summary & Detailed Earnings Play Alerts - Улправда
MBX Biosciences stock price target raised to $50 by Stifel on strong trial data By Investing.com - Investing.com Nigeria
Stifel Maintains MBX Biosciences (MBX) Buy Recommendation - Nasdaq
MBX Biosciences stock price target raised to $50 by Stifel on strong trial data - Investing.com South Africa
Is MBX Biosciences Inc. stock positioned well for digital economyJuly 2025 Trends & AI Driven Stock Reports - DonanımHaber
Aug Technicals: Will MBX Biosciences Inc. stock attract ESG investorsMarket Activity Recap & AI Enhanced Trading Alerts - Улправда
Is MBX Biosciences Inc. stock undervalued vs historical averagesJuly 2025 Sector Moves & High Accuracy Trade Signal Alerts - Улправда
S P Trends: What catalysts could drive MBX Biosciences Inc stock higherEarnings Growth Summary & Free Weekly Watchlist of Top Performers - moha.gov.vn
MBX Biosciences (MBX) faces platform validation challenge as near-term hypoglycemia data catalyst in Q2 2026 may lack differentiation - MSN
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation - Finviz
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 - The Manila Times
20 Stocks That Will Double in 2026 - Insider Monkey
EcoR1 Capital LLC Lowers Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences (NASDAQ:MBX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Walleye Capital LLC Increases Stock Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains - Seeking Alpha
MBX Biosciences, Inc. $MBX Stake Increased by Stempoint Capital LP - MarketBeat
MBX Biosciences (NASDAQ:MBX) Shares Down 5.6%Should You Sell? - MarketBeat
Resolute Capital Asset Partners LLC Acquires New Position in MBX Biosciences, Inc. $MBX - MarketBeat
Certain Common Stock of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Stock Options of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
MBX Biosciences (NASDAQ:MBX) Earns Sell Rating from Analysts at The Goldman Sachs Group - MarketBeat
MBX Biosciences (NASDAQ:MBX) Shares Gap DownHere's What Happened - MarketBeat
Goldman Sachs initiates coverage of MBX Biosciences (MBX) with sell recommendation - MSN
Goldman Sachs Initiates Coverage of MBX Biosciences (MBX) with Sell Recommendation - Nasdaq
MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM ExitWhat's Changed - Yahoo Finance
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns - Investing.com Nigeria
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns By Investing.com - Investing.com South Africa
MBX Biosciences drops 4% in premarket trading after Goldman initiates with sell - MSN
Goldman Sachs Initiates Coverage on MBX with Sell Rating | MBX S - GuruFocus
Mbx Biosciences Inc (MBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):